Xeris Biopharma CEO unveils game-changing drug innovations and record financial success

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on the company's focus on innovative drug formulation technology after reporting strong third-quarter results.

With three growing products addressing severe hypoglycemia, Cushing's Syndrome, and periodic peripheral paralysis, the company's core lies in commercial success.

Edick discussed a promising drug in development—levothyroxine—in a once-weekly subcutaneous injection format, targeting consistency and reduced side effects. Despite being in phase two, the drug could revolutionize current prescription norms.

Additionally, partnerships with industry giants like Regeneron and Amgen are underway, emphasizing Xeris' position as a formulation leader.

Financially robust, Xeris reported a record quarter and anticipates cash flow breakeven by the fourth quarter.

Edick affirmed the company's self-sustainability and projected ending 2024 with ample cash.

Despite market challenges, Xeris' growth and strategic focus signal confidence in its trajectory, positioning it as a force in biopharmaceutical innovation.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com